Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has disclosed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that release pro-inflammatory cytokines, including IL‑6 and TNF‑α, while generating reactive oxygen species (ROS) that damage DNA and trigger cell death. Thus, controlling inflammation and limiting ROS are key strategies to prevent ALI.
Most patients with myelodysplastic syndrome (MDS) exhibit variable degrees of anemia due to impaired erythropoiesis. Ameliorating anemia and reducing the dependence on transfusion may enhance the quality of life of these patients and improve their survival rates.
Eilean Therapeutics LLC has announced it is advancing ZE74-0282 into first-in-human development, with the submission of an IND application and enrollment planned to begin in the first quarter of next year.
Rona Therapeutics Co. Ltd. has announced the submission of RN-5681 to the Australian Human Research Ethics Committee (HREC), and anticipates dosing to begin in a phase I trial in the first quarter of next year.
Circle Pharma Inc. has nominated CID-165, a first-in-class, orally bioavailable macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program.
Renal fibrosis represents a key driver of the pathology of chronic kidney disease (CKD), marked by fibroblast activation, tubular damage and inflammation. Previous work found that cyclic guanosine monophosphate (cGMP) levels are markedly reduced in experimental models of renal fibrosis, but the reasons for this decline are not fully understood.
Zelluna ASA has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1 (ZIMA-101), the company’s lead candidate. ZI-MA4-1 is a novel MAGE-A4-targeting T-cell receptor-natural killer (TCR-NK) therapy.
Confo Therapeutics NV has nominated CFTX-2034 as a development candidate to treat conditions linked to hyperinsulinemic hypoglycemia, specifically post-bariatric hypoglycemia (PBH). The company is now advancing CFTX-2034 through IND-enabling studies.
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies such as tamoxifen. Recurrence is also observed in HER2+ breast cancer, even with HER2-targeted antibodies and antibody-drug conjugates (ADCs), the use of which can be limited by adverse effects such as interstitial lung disease.
RSS
